Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.

Shapiro, C L; Halabi, S; Hars, V; Archer, L; Weckstein, D; Kirshner, J; Sikov, W; Winer, E; Burstein, H J; Hudis, C; Isaacs, C; Schilsky, R; Paskett, E

Shapiro, C L; Halabi, S; Hars, V; Archer, L; Weckstein, D; Kirshner, J; Sikov, W; Winer, E; Burstein, H J; Hudis, C; Isaacs, C; Schilsky, R; Paskett, E.

Affiliation

Shapiro CL; Ohio State University Medical Center and James Cancer Hospital, Columbus, OH 43210, USA. charles.shapiro@osumc.edu

Eur J Cancer ; 47(5): 683-9, 2011 Mar.

Article in En | MEDLINE | ID: mdl-21324674

Subject(s)

Antineoplastic Agents/adverse effects; Bone Density Conservation Agents/administration & dosage; Bone Density/drug effects; Diphosphonates/administration & dosage; Imidazoles/administration & dosage; Premenopause; Primary Ovarian Insufficiency/chemically induced; Adult; Bone Density Conservation Agents/adverse effects; Breast Neoplasms/drug therapy; Chemotherapy, Adjuvant/adverse effects; Diphosphonates/adverse effects; Fatigue/chemically induced; Female; Fever/chemically induced; Humans; Imidazoles/adverse effects; Infusions, Intravenous; Middle Aged; Pain/chemically induced; Prospective Studies; Zoledronic Acid

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bone Density / Primary Ovarian Insufficiency / Premenopause / Diphosphonates / Bone Density Conservation Agents / Imidazoles / Antineoplastic Agents Type of study: Clinical_trials / Observational_studies / Risk_factors_studies Limits: Adult / Female / Humans / Middle aged Language: En Journal: Eur J Cancer Year: 2011 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google